Full Text View
Tabular View
No Study Results Posted
Related Studies
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression.
This study has been completed.
Study NCT00566202   Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: November 29, 2007   Last Updated: February 5, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Major Depressive Disorder
Additional conditions recognized in this trial
Depression
Depressive Disorder
Depressive Disorder, Major
Disease
More general conditions related to this trial
Behavioral Symptoms
Mental Disorders
Mood Disorders
Pathologic Processes
Interventions listed in this trial
placebo
JNJ-18038683
escitalopram
Additional drug interventions recognized in this trial
Citalopram
Dexetimide
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services